^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Acute Lymphocytic Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    REGIMENS FOR Ph-NEGATIVE ALL...Other Recommended Regimens...daunorubicin, vincristine, prednisone, pegaspargase, and cyclophosphamide (patients aged <60years), with rituximab for CD20-positive disease
    Secondary therapy:
    cyclophosphamide + vincristine + prednisone + daunorubicin + pegaspargase
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Regimens for Ph-negative ALL: other recommended regimens… Hyper-CVAD: hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine; with rituximab for CD20-positive disease...linker 4-drug regimen: daunorubicin, vincristine, pegaspargase, and prednisone; with rituximab for CD20-positive disease.
    Secondary therapy:
    CVAD; cytarabine + methotrexate; vincristine + prednisone + daunorubicin + pegaspargase
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Chronic Lymphocytic Leukemia)
    New
    Excerpt:
    RITUXAN (rituximab) is a CD20-directed cytolytic antibody indicated for the treatment of...Adult patients with Chronic Lymphocytic Leukemia (CLL)...Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

    Excerpt:
    ...- Diagnosis of CD20-positive ALL...
    Trial ID:
    NCT01358253
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

    Excerpt:
    ...- Histologically or immunophenotypically proven CD20-positive B-cell lymphoproliferative disorder...
    Trial ID:
    NCT00010192
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

    Excerpt:
    ...- CD20 positive disease...
    Trial ID:
    NCT00324779
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

    Excerpt:
    ...- CD20-positive disease...
    Trial ID:
    NCT00176475
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Korean J Intern Med
    Title:

    Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study

    Published date:
    06/20/2023
    Excerpt:
    In the Ph-negative ALL group, patients with higher CD20 positivity experienced more favorable RFS (p < 0.001) and OS (p = 0.06) than those with lower CD20 positivity...The addition of rituximab to conventional chemotherapy for CD20-positive ALL is effective and tolerable.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.3904/kjim.2022.401
    Trial ID:
    NCT01429610